search
Back to results

Reducing African Americans' Alzheimer's Disease Risk Through Exercise (RAATE)" (RAATE)

Primary Purpose

Dementia, Alzheimer Type

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Physical activity
Successful Aging
Sponsored by
Pennington Biomedical Research Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Dementia, Alzheimer Type focused on measuring African American, Aging, Physical activity, Cognition, Prevention

Eligibility Criteria

60 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. self- identify as African American
  2. 60 years and older
  3. willing to accept randomization
  4. willing to attend group sessions
  5. lacking plans to move during the study period
  6. free of conditions that would make regular exercise unsafe (e.g. uncontrolled asthma, severe sickle cell disease, etc.)
  7. not engaged in regular physical activity
  8. Short Physical Performance Battery score >/= 4
  9. physically capable of exercise,

Exclusion Criteria:

  1. cognitive impairment that would interfere with participating in group interactions
  2. unwilling to give written informed consent
  3. inability to attend group sessions
  4. conditions that prevent regular exercise
  5. conditions that the medical or principal investigator determine to warrant exclusion

Sites / Locations

  • Pennington Biomedical Research CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Physical activity intervention

Active control

Arm Description

The intervention group will target 150 minutes of moderate to vigorous aerobic physical activity and two days of strength training, consistent with the current physical activity recommendations. Participants will engage in 2 days per week of supervised activity at community facilities. These participants will be requested to engage in an additional 30 minutes of moderate to vigorous aerobic physical activity two days per week at home.

The active control group will be based on a low-intensity activity program and a healthy aging educational component. The physical activities will include stretching, balance training, flexibility, relaxation, and practicing activities of daily living. The successful aging education component will cover topics including avoiding scams, fall prevention, living wills, and dementia awareness.

Outcomes

Primary Outcome Measures

Change in episodic memory
The Rey Auditory Verbal Learning Test (RAVLT) is a common neuropsychological tool used to evaluate episodic memory. The RAVLT involves providing participants with 15 unrelated words and asking them to recall the word list. There are 5 trials designed to determine short-term memory and then a 30 minute delay to assess long-term memory. The total words correct in both the short- and long-term trials are used as outcome measures.
Change in executive function
The NIH Toolbox Executive Function subdomain consists of the Flanker Inhibitory Control and Attention Test and the Dimensional Change Card Sort Test. The Flanker test is a measure of one's ability to inhibit attention to irrelevant conditions. Participants must identify the direction of a central visual stimuli amongst flanking stimuli either congruent or incongruent with the central stimuli. There are 40 trials and scores range from 0 - 10. The Card Sort is a measure of the ability to shift attention based on rules. Participants must match a target visual stimuli to either a color or word stimuli and this matching shifts during the assessment.

Secondary Outcome Measures

Change in cognitive status
The Mini-Mental Status Examination is 30-point questionnaire to assess cognitive impairment.
Change in glucose
Fasting levels of glucose will be assessed using standard assays.
Change in time spent in physical activity
The Actigraph WGT3X+ accelerometer (ActiGraph LLC, Pensacola, FL) will be worn by the participant for a 7-day period. The device provides both the number of steps per day as well as time in sedentary, light, moderate, and vigorous activity in 1-minute epochs (for adults) using the default filter.
Change in cardiorespiratory fitness
All participants will perform a standardized graded exercise testing protocol administered on a treadmill. Fitness will be measured in terms of mL oxygen/kg/min.
Change in physical function-NIH Toolbox
Physical function will be assessed using the NIH-TB Motor assessment, which assesses dexterity, balance, locomotion, grip strength, and strength.
Change in telomere length
DNA will be extracted from the blood draw and amplified using real-time quantitative polymerase chain reaction (qPCR) to determine average relative telomere length represented by the telomere repeat copy number to single gene copy number (T/S) ratio in triplicate as previously described
Change in weight
Weight will be measured using a standard stadiometer. Measurements will be taken to the nearest cm.
Change in brain structure
Volumes of the cranial vault, brain tissue, gray matter, white matter, and cerebrospinal fluid, which will be provided as the primary brain structural outcome measures of interest from MRI.
Changes in brain function
Pre-selected inhibitory control ROIs (ACC for the Stroop; DLPFC, thalamus, superior frontal, inferior frontal, fusiform, and middle frontal gyri; and ACC and middle frontal gyri for the ANT) are of primary interest.
Change in lipoproteins
Fasting levels of lipids will be assessed using standard assays.
APOE genotype
APOE genotype will be assessed using standard assays.
Change in physical activity
The Fitbit Charge 2 will be worn by participants in both groups.
Change in blood pressure
Blood pressure will be measured using the Omron, Model BP710 automatic blood pressure cuff.
Change in mood
The Geriatric Depression Scale will be used to measure depressive symptoms.
Change in height
Height will be assessed using a standard stadiometer.
Change in physical function-SPPB
Physical function will be assessed using the the Short Physical Performance Battery (SPPB), which is a brief performance battery based on timed short distance walk, repeated chair stands and balance test.

Full Information

First Posted
March 18, 2019
Last Updated
January 28, 2023
Sponsor
Pennington Biomedical Research Center
Collaborators
National Institute on Aging (NIA)
search

1. Study Identification

Unique Protocol Identification Number
NCT03890861
Brief Title
Reducing African Americans' Alzheimer's Disease Risk Through Exercise (RAATE)"
Acronym
RAATE
Official Title
Reducing African Americans' Alzheimer's Disease Risk Through Exercise (RAATE)"
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 9, 2019 (Actual)
Primary Completion Date
June 2025 (Anticipated)
Study Completion Date
November 30, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Pennington Biomedical Research Center
Collaborators
National Institute on Aging (NIA)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The RAATE proposal is designed to determine the effects of physical activity on risk factors for Alzheimer's Disease in older African American adults. The study will compare a physical activity program to an active control group. There are three main objectives of the protocol: 1) to determine if a physical activity intervention tailored to older African American adults is effective in modifying cognitive function associated with Alzheimer's Disease, 2) to determine if a physical activity intervention tailored to older African American adults is effective in modifying brain function and structure associated with Alzheimer's Disease, and 3) to determine if a physical activity promotion intervention tailored to African American adults is effective at enhancing physiological parameters. The primary endpoints for the study are episodic memory and executive functioning. The secondary outcomes include anthropometry, blood pressure, brain activation, cerebral blood flow, volume of whole brain and white matter hyperintensities, cardiorespiratory fitness, objectively measured physical activity, circulating hormones, and telomere length.
Detailed Description
Alzheimer's disease is steadily increasing in prevalence, with a devastating public health impact. The prevalence of Alzheimer's Disease is higher in African Americans compared to white Americans, thereby constituting a health disparity. Interventions that prevent Alzheimer's disease or change the course of cognitive decline associated with Alzheimer's disease are needed. Most older adults do not achieve recommended levels of physical activity, and this includes African Americans. Regular physical activity has proven to be a safe and effective means to enhance cognitive function in older adults ranging from cognitively healthy to mildly cognitively impaired. Therefore, our study is focused on physical activity promotion, a potent approach to modifying multiple neurobiological pathways implicated in Alzheimer's Disease. We evaluate exercise benefits among elderly African Americans, who are understudied and in whom the natural course of neurodegeneration, exercise effects on neuroprotection and neurodegeneration, and resulting clinical phenotypes may differ. A large body of existing data suggests that exercise improves cardiovascular and cerebrovascular functioning, and thus has the potential to enhance perivascular clearance of amyloid and reduce chronic brain tissue ischemia, among other beneficial effects. At the same time, chronic exercise has been shown to decrease central levels of inflammatory markers and increase central levels of neurotrophic factors, which in turn promote protection against Alzheimer's Disease neurodegeneration pathways via a variety of mechanisms. While physical activity interventions have been shown to have positive effects on these factors and on resultant cognitive functioning in older adults, nearly all interventions have had a negligible representation of African Americans. Prior data suggests that African Americans enter their elderly years against a backdrop of different lifespan exposures to a variety of factors relevant to neuroprotection and neurodegeneration, including cardiovascular risk, exercise, diet, and education. In addition, prior data suggests that the key genetic risk factor for Alzheimer's Disease (APOE) may have differing consequences for Alzheimer's Disease risk among African Americans, and other genetic differences have the potential to influence the brain benefits of physical activity in this community. We will utilize a randomized clinical trial to addresses these questions. Participants will be randomized into a physical activity promotion intervention or a healthy aging information group for 52 weeks. All participants will be of normal cognitive function. We will assess cognitive function, brain structure and function, circulating hormones, objectively measured physical activity, cardiorespiratory fitness, and telomere length. Our study will take the first step toward understanding whether the hypothesized benefits of exercise for the brain carry over to elderly African Americans.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dementia, Alzheimer Type
Keywords
African American, Aging, Physical activity, Cognition, Prevention

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Physical activity intervention
Arm Type
Experimental
Arm Description
The intervention group will target 150 minutes of moderate to vigorous aerobic physical activity and two days of strength training, consistent with the current physical activity recommendations. Participants will engage in 2 days per week of supervised activity at community facilities. These participants will be requested to engage in an additional 30 minutes of moderate to vigorous aerobic physical activity two days per week at home.
Arm Title
Active control
Arm Type
Active Comparator
Arm Description
The active control group will be based on a low-intensity activity program and a healthy aging educational component. The physical activities will include stretching, balance training, flexibility, relaxation, and practicing activities of daily living. The successful aging education component will cover topics including avoiding scams, fall prevention, living wills, and dementia awareness.
Intervention Type
Behavioral
Intervention Name(s)
Physical activity
Intervention Description
Promotion of physical activity to the current federal physical activity guidelines.
Intervention Type
Behavioral
Intervention Name(s)
Successful Aging
Intervention Description
Seminars of health topics related to aging in African Americans with light stretching and low intensity activites
Primary Outcome Measure Information:
Title
Change in episodic memory
Description
The Rey Auditory Verbal Learning Test (RAVLT) is a common neuropsychological tool used to evaluate episodic memory. The RAVLT involves providing participants with 15 unrelated words and asking them to recall the word list. There are 5 trials designed to determine short-term memory and then a 30 minute delay to assess long-term memory. The total words correct in both the short- and long-term trials are used as outcome measures.
Time Frame
Baseline, 24 weeks, 52 weeks
Title
Change in executive function
Description
The NIH Toolbox Executive Function subdomain consists of the Flanker Inhibitory Control and Attention Test and the Dimensional Change Card Sort Test. The Flanker test is a measure of one's ability to inhibit attention to irrelevant conditions. Participants must identify the direction of a central visual stimuli amongst flanking stimuli either congruent or incongruent with the central stimuli. There are 40 trials and scores range from 0 - 10. The Card Sort is a measure of the ability to shift attention based on rules. Participants must match a target visual stimuli to either a color or word stimuli and this matching shifts during the assessment.
Time Frame
Baseline, 24 weeks, 52 weeks
Secondary Outcome Measure Information:
Title
Change in cognitive status
Description
The Mini-Mental Status Examination is 30-point questionnaire to assess cognitive impairment.
Time Frame
Baseline, 24 weeks, 52 weeks
Title
Change in glucose
Description
Fasting levels of glucose will be assessed using standard assays.
Time Frame
Baseline, 24 weeks, 52 weeks
Title
Change in time spent in physical activity
Description
The Actigraph WGT3X+ accelerometer (ActiGraph LLC, Pensacola, FL) will be worn by the participant for a 7-day period. The device provides both the number of steps per day as well as time in sedentary, light, moderate, and vigorous activity in 1-minute epochs (for adults) using the default filter.
Time Frame
Baseline, 24 weeks, 52 weeks
Title
Change in cardiorespiratory fitness
Description
All participants will perform a standardized graded exercise testing protocol administered on a treadmill. Fitness will be measured in terms of mL oxygen/kg/min.
Time Frame
Baseline, 24 weeks, 52 weeks
Title
Change in physical function-NIH Toolbox
Description
Physical function will be assessed using the NIH-TB Motor assessment, which assesses dexterity, balance, locomotion, grip strength, and strength.
Time Frame
Baseline, 24 weeks, 52 weeks
Title
Change in telomere length
Description
DNA will be extracted from the blood draw and amplified using real-time quantitative polymerase chain reaction (qPCR) to determine average relative telomere length represented by the telomere repeat copy number to single gene copy number (T/S) ratio in triplicate as previously described
Time Frame
Baseline, 24 weeks, 52 weeks
Title
Change in weight
Description
Weight will be measured using a standard stadiometer. Measurements will be taken to the nearest cm.
Time Frame
Baseline, 24 weeks, 52 weeks
Title
Change in brain structure
Description
Volumes of the cranial vault, brain tissue, gray matter, white matter, and cerebrospinal fluid, which will be provided as the primary brain structural outcome measures of interest from MRI.
Time Frame
Baseline, 24 weeks, 52 weeks
Title
Changes in brain function
Description
Pre-selected inhibitory control ROIs (ACC for the Stroop; DLPFC, thalamus, superior frontal, inferior frontal, fusiform, and middle frontal gyri; and ACC and middle frontal gyri for the ANT) are of primary interest.
Time Frame
Baseline, 24 weeks, 52 weeks
Title
Change in lipoproteins
Description
Fasting levels of lipids will be assessed using standard assays.
Time Frame
Baseline, 24 weeks, 52 weeks
Title
APOE genotype
Description
APOE genotype will be assessed using standard assays.
Time Frame
Baseline
Title
Change in physical activity
Description
The Fitbit Charge 2 will be worn by participants in both groups.
Time Frame
Continuously for 52 weeks
Title
Change in blood pressure
Description
Blood pressure will be measured using the Omron, Model BP710 automatic blood pressure cuff.
Time Frame
Blood pressure will be measured using the Omron, Model BP710 automatic blood pressure cuff.
Title
Change in mood
Description
The Geriatric Depression Scale will be used to measure depressive symptoms.
Time Frame
Baseline, 24 weeks, 52 weeks
Title
Change in height
Description
Height will be assessed using a standard stadiometer.
Time Frame
Baseline, 24 weeks, 52 weeks
Title
Change in physical function-SPPB
Description
Physical function will be assessed using the the Short Physical Performance Battery (SPPB), which is a brief performance battery based on timed short distance walk, repeated chair stands and balance test.
Time Frame
Baseline, 24 weeks, 52 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: self- identify as African American 60 years and older willing to accept randomization willing to attend group sessions lacking plans to move during the study period free of conditions that would make regular exercise unsafe (e.g. uncontrolled asthma, severe sickle cell disease, etc.) not engaged in regular physical activity Short Physical Performance Battery score >/= 4 physically capable of exercise, Exclusion Criteria: cognitive impairment that would interfere with participating in group interactions unwilling to give written informed consent inability to attend group sessions conditions that prevent regular exercise conditions that the medical or principal investigator determine to warrant exclusion
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Melissa Harris, PhD
Phone
225763091
Email
Melissa.Harris@pbrc.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert L Newton, Jr., PhD
Organizational Affiliation
Pennington Biomedical Research Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Owen L Carmichael, PhD
Organizational Affiliation
Pennington Biomedical Research Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Pennington Biomedical Research Center
City
Baton Rouge
State/Province
Louisiana
ZIP/Postal Code
70808
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Melissa Harris, MA
Phone
225-763-3091
Email
Melissa.Harris@pbrc.edu
First Name & Middle Initial & Last Name & Degree
Jessica St. Romain, MA
Phone
2257632921
Email
Jessica.Stromain@pbrc.edu
First Name & Middle Initial & Last Name & Degree
Robert L Newton, Jr., PhD
First Name & Middle Initial & Last Name & Degree
Owen Carmichael, PhD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
For all study data, Pennington Biomedical has a well-structured internal process for data sharing and transfer. The Office of Legal and Regulatory Compliance is responsible for all data agreements which includes data subject to the protection under HIPAA. As part of the Louisiana State University System, Pennington Biomedical ensures that data agreements are in place in the following circumstances: business associate agreements when the transfer of data contains all identifiers, data use agreements when the transfer of data contains those identifiers that constitute a limited data set and a data transfer agreement in instances where data is de-identified, but still may be subject of protection in order to protect intellectual property rights. Transmission of data to ensure proper safeguards are in place on the data in motion and data at reset are carried out with assistance of the Research Computing Group or the Office of Computing Services.
IPD Sharing Time Frame
Data will be available after data analysis has occurred.

Learn more about this trial

Reducing African Americans' Alzheimer's Disease Risk Through Exercise (RAATE)"

We'll reach out to this number within 24 hrs